The Efficacy, Safety, and Cost Benefit of Olanzapine versus Aprepitant in Highly Emetogenic Chemotherapy: A Pilot Study from South India

<table class="table-group" id="tab4"><tr><td><table class="table"><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr class="thead"><td class="align_left">Chemotherapy regimen</td><td class="align_center">APD  arm</td><td class="align_center">OPD arm</td></tr><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr><td class="align_left">FEC 100/FAC</td><td class="align_center">25</td><td class="align_center">26</td></tr><tr><td class="align_left">CHOP or ABVD</td><td class="align_center">9</td><td class="align_center">7</td></tr><tr><td class="align_left">CDDP/5FU or CDDP paclitaxel</td><td class="align_center">9</td><td class="align_center">10</td></tr><tr><td class="align_left">IAP</td><td class="align_center">5</td><td class="align_center">5</td></tr><tr><td class="align_left">ECF</td><td class="align_center">2</td><td class="align_center">2</td></tr><tr class="table-tr"><td colspan="3"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

Antiemetic intervention for each regimen.

Chemotherapy Research and Practice

tab4

Table 4

Table 4: The Efficacy, Safety, and Cost Benefit of Olanzapine versus Aprepitant in Highly Emetogenic Chemotherapy: A Pilot Study from South India 